Psilocybin and the microbiome

The available literature (2016–2026) shows that psilocybin/psilocin measurable gastrointestinal (GI) effects can have, but that the Direct human data on gut function and gut microbiome are scarce. is. In human RCTs with therapeutic doses (usually 25 mg orally) become nausea (typical ~4–48%, depending on the study and measurement method) and less often vomiting and diarrhea reported; most GI complaints are short-term (hours to <48 hours) and occur mainly around the dosing day.

Pharmacokinetically, psilocybin is a prodrug that in vivo is rapidly dephosphorylated to psilocin, with a after oral administration Tmax for psilocin of ~1.8–4 hours and a elimination half-life (psilocin) of roughly ~2–4.8 hours; metabolism proceeds mainly via glucuronidation (UGTs, incl. intestinal UGT1A10) and to a lesser extent via MAO-A/CYPs, followed by elimination primarily renal takes place; a Biliary fraction (order of magnitude 15–20%) is described in (particularly) toxicological/forensic literature and animal data.

Animal studies that explicitly measure the microbiome show no consistent change in global diversity, but taxonomic shifts (rat: oa. Verrucomicrobia; mouse: reductions in oa. Lactobacillus- and Alistipes-species) and in one mouse model a dose-dependent effect on intestinal motility with chronic administration. Human studies with fecal 16S/metagenomics before/after psilocybin are largely absent from the core peer-reviewed literature.

For immunomodulation the picture is mixed: there are indications for anti-inflammatory effects (including acute decline in systemic TNF-α and IL‑6/CRP after 7 days in healthy volunteers), but preclinical syntheses emphasize that psychedelics under 'normal' circumstances sometimes also pro-inflammatory signals can enhance; in intestinal cell/tissue models, psilocybin reduces multiple pro-inflammatory mediators.

Key research gaps are: lack of human microbiome and metabolomics data (incl. SCFAs), insufficient direct measurements of motility/secretion/barrier permeability in humans, and uncertainty regarding the clinical relevance of hypothetical pathways such as (entero)hepatic recycling of psilocin-glucuronides in interaction with microbial β‑glucuronidase.

Delimitation and quality of the evidence

This report focuses on psilocybin (synthetic/pharmaceutical or as an isolated substance) and its active metabolite psilocin, with emphasis on: pharmacokinetics, local GI effects, microbiome, intestinal immunology, and clinical GI adverse effects. The core of the evidence consists of (i) humane RCTs in which GI outcomes are almost always as adverse events (AEs) are registered, (ii) preclinical studies with targeted microbiome or motility measurements, and (iii) mechanistic In vitro/ex vivo models of intestinal inflammation.

Methodologically, there are recurring limitations: functional unblinding (classic problem with psychedelics), heterogeneous AE registration (solicited vs spontaneous), limited follow-up for somatic outcomes, small sample sizes, and often in microbiome studies 16S at the (sub)taxonomic level without metabolomics.

Pharmacokinetics and enteric processing

Absorption and conversion of psilocybin → psilocin

Psilocybin is produced in vivo rapidly dephosphorylated to psilocin; in a recent systematic review, the Tmax values for psilocin after oral psilocybin typical between ~1.8 and 4 hours (human data), with clear variation due to dose and design.

Dephosphorylation is linked in the literature to (intestinal) alkaline phosphatase and non-specific esterases; the point that intestinal alkaline phosphatase is relevant in the enteric context is explicitly mentioned in recent review literature, among others.

Metabolism: glucuronidation as the dominant route and the role of intestinal UGTs

Psilocin undergoes extensive phase II metabolism (glucuronidation). In vitro enzyme work shows that especially UGT1A10 has a high capacity for psilocin glucuronidation and that this UGT prominent in the small intestine is expressed—which offers a plausible mechanism for intestinal first-pass glucuronidation.

In addition, recent metabolism studies and reviews describe contributions from UGT1A9 (more hepatic) and a smaller role of MAO-A and CYPs (including CYP2D6/CYP3A4) in secondary pathways (such as 4‑HIAA/related metabolites).

Elimination and (hypotheses regarding) enterohepatic components

In human PK syntheses, elimination is predominantly renal, with half-lives (psilocin) after oral administration in the order ~2–4.8 hours.

A biliary excretory fraction is mentioned in (particularly) toxicological/forensic sources and recent review articles (order of magnitude) ~15–20%), with animal data showing excretion within hours after administration via bile and feces to show.

Entorohepatic Cycle (EHK) in the strict sense, however, requires not only biliary excretion, but also deconjugation in the intestine and reabsorption. Direct, psilocybin-specific human ECG data (e.g., measured 'secondary peaks', bile sampling, tracer studies) are present in the recent peer-reviewed core literature. not robustly documented; what is strongly substantiated, however, is that the gut microbiota β‑glucuronidase-possesses enzymes that can hydrolyze glucuronides and thereby (in general) promote enterohepatic recirculation of some substances—a mechanism that may be theoretically relevant for psilocin-glucuronide, but has not yet been sufficiently directly tested.

flowchart LR A[Oral ingestion of psilocybin] --> B[Intestine: de-phosphorylation to psilocin] B --> C[Absorption -> portal circulation] C --> D[Intestinal first-pass: UGT1A10 -> psilocin-O-glucuronide] C --> E[Liver: UGT1A9 + MAO-A/CYPs -> secondary metabolites] D --> F[Elimination: mainly urine] E --> F E --> G[Part via bile/feces] G --> H[In intestine: microbial β-glucuronidase -> deconjugation? (hypothesis)] B --> I[Local 5-HT receptor action (ENS/epithelium)] I --> J[Motility/secretion/visceral sensation -> GI symptoms] I --> K[Vagus/ANS -> central-peripheral feedback] I --> L[Immunomodulation in mucosa (cytokines/barrier)] L --> M[Possible microbiome shifts]

The sections “deconjugation? (hypothesis)” and “possible microbiome shifts” are explicitly stated as insecure marked because direct human data is limited.

Local gastrointestinal effects

Motility

Serotonergic signaling is deeply intertwined with GI physiology: 5-HT in the gut modulates, among other things. motility/transit, secretion and visceral sensitivity, and multiple 5-HT receptor families are present in the GI system.

For psilocybin-specific effects on motility, the strongest direct evidence comes from a recent mouse study with chronic oral bloating (0.1 and 1 mg/kg), in which a dose-dependent effect on intestinal motility was reported. Details regarding direction/clinical equivalence are model- and measurement method-dependent; the key point is that motility itself changed as an outcome upon repeated exposure.

Mechanistically, this is biologically plausible because 5‑HT2A‑receptors (the primary central target of psilocin) also occur in the gut on, among others. smooth muscle cells and enteric neurons.

Secret

Direct, psilocybin-specific measurements of intestinal secretion in humans (e.g., chloride secretion, water flux, gut hormones in relation to GI symptoms) have been found in recent clinical literature. usually unspecified; what is firmly substantiated, however, is that serotonin in general can affect secretory reflexes and mucosal functions.

Mucosal integrity and barrier function

There is growing literature suggesting that serotonergic signaling and stress-related 5-HT dynamics the intestinal barrier function can influence, including effects on tight-junction-related processes in experimental models.

For psilocybin itself, there is direct evidence regarding barrier function in humans. hardly available; intestinal inflammation models at the tissue/cell level (see next section) primarily provide information about inflammatory mediators and less about hard barrier measurements (TEER/permeability).

Effects on gut microbiome and microbial metabolites

Human data: virtually no direct microbiome research

In the most important human therapeutic RCTs, the microbiota is usually not central; there are (in the core sources identified here) no standard fecal 16S/metagenomics series as a primary outcome before/after psilocybin. Consequently, any statement regarding “microbiome improvement” in humans is currently primary hypothesis-driven.

Animal data: composition and diversity

There are, however, recent preclinical studies that measure microbiome changes after psilocybin:

1. In rats (male Long Evans) after single oral gag of 0.2 mg/kg (“low”) or 2 mg/kg (“high”) no significant effect was found on Shannon diversity (at the phylum level), but indeed phylum-specific shifts, including an increase in Verrucomicrobia at week 1 (low) and week 3 (high), while dominant phyla (Firmicutes/Bacteroidetes) remained relatively stable.

2. In mice at chronic oral bloating (0.1 and 1 mg/kg) also showed no significant change in global diversity reported, but species-level reductions (among others). Lactobacillus murinus, Lactobacillus animalis, Alistipes dispar) in male wild-type animals, with sex and genotype dependence.

Functional changes and metabolites (incl. SCFA)

The available animal studies above are methodologically primarily 16S-based and focus primarily on taxonomy; direct measurements of microbial metabolites (such as SCFAs: acetate, propionate, butyrate), secondary bile acids, or broad fecal metabolome are in these core studies not reported / unspecified.

This leaves an important knowledge gap: if psilocybin truly acts (partly) via the microbiota, then the mechanism is best tested via integrated metagenomics + metabolomics and linkage to (i) motility, (ii) inflammatory markers, and (iii) pharmacokinetics (psilocin/psilocin-glucuronide). Review articles on psychedelics and the microbiota-gut-brain axis explicitly mention this as a research agenda.

Immunomodulation in the gut

Intestinal inflammation and mucosal mediator profiles

There are intestine-targeted experimental models that point to anti-inflammatory potential:

1. In a human 3D Epiintestinal tissue model with TNF-α/IFN-γ-induced inflammation, psilocybin reduced several pro-inflammatory mediators (including TNF-α, IFN-γ, IL-6, IL-8, MCP-1, GM-CSF) in the assay context.

2. In human small intestine epithelial cell experiments, it has also been reported that psilocybin (and related 5-HT2A ligands) can reduce inflammatory markers (such as COX-2/IL-6 in specific designs); however, mechanistic interpretations remain provisional and model-dependent.

Important: these types of models are not the same as clinical IBD or IBS—they provide indications for direction (“can suppress inflammatory mediators”) but do not prove clinical efficacy in bowel diseases.

Systemic immune markers in humans and relevance to the gut

In healthy volunteers, psilocybin (0.17 mg/kg; placebo-controlled) has been associated with acute drop in TNF‑α and more persistent decline of IL‑6 and CRP after 7 days; this concerns systemic markers, but is relevant because systemic inflammation and gut-brain axis processes can influence each other.

Other human data suggest that cytokine responses not uniform be and can vary depending on context or population (e.g., transience and inconsistency across populations).

Finally, preclinical syntheses (cross-psychedelic) emphasize that classical psychedelics often in animal and in vitro studies anti-inflammatory effects show signs of pre-existing inflammation, but that there are also indications for pro-inflammatory effects when administered under “normal” physiological conditions—which underscores the need to explicitly measure intestinal outcomes in controlled clinical trials.

Clinical side effects and differences between animal and human data

Summary table of relevant human and animal studies

Table of gastrointestinal side effects and frequencies

The frequencies below are derived from well-documented RCTs and a systematic AE review; differences are strongly associated with context, ascertainment (solicited vs spontaneous), and comparator.

Animal versus human: what translates and what doesn't?

At human studies its GI effects are mainly visible when symptom-AEs (nausea, sometimes vomiting/diarrhea), while objective GI physiology (motility measurements, secretion tests, barrier time series, fecal biomarkers) is rarely measured.

At animal studies While it is possible to collect feces directly and test (chronic) motility, signals appear to suggest that psilocybin can influence motility and microbiome composition, but with strong dependence on species, sex, genotype, and dosage schedule. Extrapolation to humans is uncertain due to (i) mg/kg to mg translation, (ii) differences in diet/housing, (iii) 16S resolution and batch effects, and (iv) the fact that “set & setting” differs fundamentally in animals.

Uncertainties, methodological limitations, and research gaps

A core uncertainty is the causal direction between (a) psilocybin → microbiome shifts → GI function/immune, versus (b) psilocybin → neural/ANS changes → motility/secretion → secondary microbiome shifts. The mouse data with correlation clusters support “feedback” hypotheses but do not prove causality.

For enterohepatic circulation There is a lack of specific, modern human evidence (bile sampling, tracer design) for psilocin-glucuronides; at the same time, the underlying microbial mechanism (β-glucuronidase hydrolysis) is so general that it is testable and must be regarded as a plausible interaction route, not as an established fact.

Microbiome studies to date are limited by: small n, one sex (rat), single vs. chronic scheme, taxonomic focus, and absence of metabolomics (SCFAs, bile acids, tryptophan metabolites) and host readouts (fecal calprotectin, zonulin/permeability assays).

Finally, clinical AE frequencies are sensitive to measurement strategy: solicited symptom checklists yield higher incidences (such as nausea 48%) than spontaneous reporting or “≥3 patients” tables, making cross-trial comparison without harmonization methodologically risky.